Amicus Therapeutics (NASDAQ:FOLD) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a research report released on Tuesday.

Other equities research analysts also recently issued reports about the stock. Morgan Stanley dropped their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald boosted their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Jefferies Financial Group began coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 target price for the company. Finally, Guggenheim increased their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.63.

Amicus Therapeutics Stock Down 0.1 %

Amicus Therapeutics stock opened at $10.15 on Tuesday. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $3.03 billion, a P/E ratio of -29.85 and a beta of 0.60. The firm has a 50 day moving average price of $10.55 and a 200-day moving average price of $10.61. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $11.46, for a total value of $85,950.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,161,054.84. The trade was a 0.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 30,401 shares of company stock worth $339,363 over the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OLD Second National Bank of Aurora bought a new stake in Amicus Therapeutics in the 3rd quarter worth $26,000. Hazlett Burt & Watson Inc. raised its stake in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,569 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics during the 3rd quarter valued at about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Amicus Therapeutics during the 3rd quarter valued at approximately $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.